3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 240
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Sheldon L. Koenig | President, CEO & Director | 1,2M | S.O. | 1966 |
Mr. Benjamin O. Looker | General Counsel | 550,35k | S.O. | 1982 |
Dr. JoAnne Micale Foody FACC, M.D. | Chief Medical Officer | 771,19k | S.O. | 1966 |
Mr. Benjamin Halladay M.B.A. | Chief Financial Officer | S.O. | S.O. | 1986 |
Mr. Glenn P. Brame | Chief Technical Operations Officer | S.O. | S.O. | 1958 |
Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications | S.O. | S.O. | S.O. |
Ms. Betty Jean Swartz | Chief Business Officer | S.O. | S.O. | S.O. |
Mr. Eric J. Warren R.Ph. | Chief Commercial Officer | S.O. | S.O. | 1972 |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
L’ISS Governance QualityScore de Esperion Therapeutics, Inc. en date du 1 mars 2024 est 7. Les scores principaux sont Audit : 4; Société : 5; Droits des actionnaires : 8; Compensation : 9.